Regeneron's antibody curbs POTS heart rate spikes in mid-stage trial
Regeneron announced that its experimental monoclonal antibody, baloncibart, met its primary goal in a Phase 2 trial for postural orthostatic tachycardia syndrome, a chronic condition with no FDA-approved treatments.
Original image temporarily unavailable
Clinical Trial Results
Regeneron reported data from its Phase 2 Pinnacle trial evaluating baloncibart, also known as REGN7544, in 82 patients with postural orthostatic tachycardia syndrome (POTS). Patients receiving a 450-mg injection experienced a mean drop in heart rate of 11.4 beats per minute compared to placebo at day eight, while a 150-mg dose reduced heart rate by 9.5 beats per minute. The high-dose group also showed sustained heart rate reductions and reported improvements in physical functioning at day 29.
Mechanism and Development
POTS is a chronic autonomic nervous system disorder associated with lightheadedness and fatigue, with no currently approved treatments. Baloncibart is an NPR1-blocking monoclonal antibody designed to increase blood volume in circulation. Regeneron plans to launch a Phase 3 study in the first half of 2027, building on this mid-stage success.
View selection rationale
Importance 75/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- BioSpace Drug Development ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.